+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "PCSK9 Inhibitor"

From
From
From
From
From
From
From
From
From
From
From
Dyslipidemia Market Report and Forecast 2024-2032 - Product Thumbnail Image

Dyslipidemia Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
Antihyperlipidemic Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Antihyperlipidemic Drugs Market Report and Forecast 2024-2032

  • Report
  • September 2023
  • 160 Pages
  • Global
From
Loading Indicator

The PCSK9 Inhibitor market is a subset of the Cardiovascular Drugs market. PCSK9 Inhibitors are a class of drugs used to lower cholesterol levels in patients with cardiovascular disease. These drugs work by blocking the action of the PCSK9 enzyme, which is responsible for breaking down LDL cholesterol in the body. PCSK9 Inhibitors are typically prescribed in combination with other cholesterol-lowering medications, such as statins. PCSK9 Inhibitors have been shown to be effective in reducing LDL cholesterol levels, and have been approved for use in the United States and Europe. However, due to their high cost, they are not widely used. Companies in the PCSK9 Inhibitor market include Amgen, Sanofi, Regeneron, and Pfizer. Show Less Read more